STOCK TITAN
  1. Home
  2. Sec-filings
  3. PCRX
  4. [Form 4] Pacira BioSciences, Inc. Insider Trading Activity

Pacira BioSciences (PCRX) director granted 32,675 stock options at $23.42

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Pacira BioSciences director Thomas G. Wiggans received a stock option grant for 32,675 shares of common stock. The option has an exercise price of $23.42 per share and expires on June 10, 2036. One-third of the option vests on the first anniversary of the grant, with the remaining shares vesting in equal monthly installments over the following two years, as long as he remains in continuous service. After this grant, he holds options for 32,675 shares.

Positive

  • None.

Negative

  • None.
Insider WIGGANS THOMAS G
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 32,675 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 32,675 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 32,675 shares Stock Option (Right to Buy) granted to director on June 10, 2026
Exercise price $23.42 per share Conversion or exercise price of the stock option grant
Expiration date June 10, 2036 Option expiration for the 32,675-share grant
Shares underlying option 32,675 shares Underlying Pacira common stock covered by the new option
Post-transaction option holdings 32,675 options Total options held by Wiggans following this grant
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
conversion or exercise price financial
"conversion_or_exercise_price: 23.4200"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
vests and becomes exercisable financial
"The stock option vests and becomes exercisable as to one-third of the option shares"
continuous service financial
"provided that the reporting person remains in continuous service with the issuer"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WIGGANS THOMAS G
(Last)(First)(Middle)
C/O PACIRA BIOSCIENCES, INC.
2000 SIERRA POINT PARKWAY, SUITE 900
(Street)
BRISBANE CALIFORNIA 94005
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$23.4206/10/2026A32,675 (1)06/10/2036Common Stock32,675$032,675D
Explanation of Responses:
1. The stock option vests and becomes exercisable as to one-third of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal monthly installments over the subsequent two years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
Remarks:
/s/ Kristen Williams, Attorney-in-Fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Pacira BioSciences (PCRX) director Thomas Wiggans report on this Form 4?

Thomas G. Wiggans reported receiving a stock option grant for 32,675 shares of Pacira BioSciences common stock. These options were granted at an exercise price of $23.42 per share as part of his director compensation.

How many Pacira BioSciences (PCRX) options did Thomas Wiggans receive and hold after the grant?

He received options covering 32,675 shares and held options for 32,675 shares following the transaction. This filing shows only this single grant, with no additional derivative positions listed afterward.

What is the exercise price and expiration date of the PCRX options granted to Thomas Wiggans?

The options have an exercise price of $23.42 per share and expire on June 10, 2036. This defines the price at which he can buy Pacira BioSciences common stock before the expiration date.

How do the Pacira BioSciences (PCRX) options granted to Thomas Wiggans vest?

One-third of the 32,675 option shares vest on the first anniversary of the June 10, 2026 grant date. The remaining two-thirds vest in equal monthly installments over the subsequent two years, contingent on his continuous service.

Is the Pacira BioSciences (PCRX) Form 4 transaction a market purchase or sale?

No market trade occurred. The Form 4 reports a compensation-related grant of stock options with a transaction code "A" (grant, award, or other acquisition), not an open-market buy or sell of common shares.